/ /

  • linkedin
  • Increase Font
  • Sharebar

    Intranasal neurostimulation increases tear production, improves dry eye signs/symptoms

    Intranasal neurostimulation (TrueTear, Allergan) increases aqueous tear production in patients with moderate-to-severe aqueous deficiency dry eye disease (DED). In addition, the therapy maintains its benefit over 180 days of use, and continues to be safe and well-tolerated, according to results of an open-label study conducted to evaluate the long-term safety and effectiveness of the recently approved novel treatment.

    Data collected in the study also demonstrated that the treatment improved corneal fluorescein staining (CFS) and symptoms, said Edward J. Holland, MD, professor of ophthalmology, University of Cincinnati, Cincinnati, OH.

    “Certainly, the overall results of this research suggest that intranasal neurostimulation could be a potential treatment option to increase tear production in patients with moderate-to-severe DED,” Dr. Holland said. “We look forward to further clinical trials investigating this device.”

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results